Gabapentin paten?

Quick take‑away

Gabapentin is off‑patent worldwide. The original Pfizer patents that covered the drug’s discovery and basic formulation expired in the 1990s, and subsequent “use” and “formulation” patents have since lapsed or were abandoned. Generics have been on the market since the early 2010s, and most countries no longer grant exclusivity for gabapentin.

Below is a concise rundown of the key patents, their status, and what that means for the drug today.

What does this mean for developers / prescribers?

1. Generic availability

   • The U.S., EU, Canada, Australia, and most other major markets have multiple generic manufacturers offering 300 mg, 400 mg, 600 mg, 800 mg, and 1200 mg tablets/creams.
   • Prices have dropped dramatically (often < $1 per 300 mg tablet in bulk).

2. Innovation still possible

   • While the core molecule is free, there are still valid patents on novel delivery devices, extended‑release formulations, and combination products (e.g., gabapentin + acetaminophen).
   • If you’re developing a new dosage form, delivery system, or drug‑delivery device that truly differs from existing patented products, you can still protect that innovation.

3. Regulatory filings

   • In the U.S., a “Abbreviated New Drug Application” (ANDA) can be filed for any generic that meets the FDA’s “Abbreviated” criteria.
   • The FDA’s Orange Book lists the active patents and exclusivities that apply; after they expire you can launch generics.

4. Global considerations

   • Some low‑ and middle‑income countries (LMICs) may still have national exclusivities that delay generic entry. Check local patent registers.
   • For commercial ventures in those markets, you’ll need to review the specific national filings.

How to check the current status for a specific claim

If you’re planning a new formulation or product line, the best next step is to run a patent landscape analysis with these databases, focusing on claims that are still in force or pending. That will tell you whether you need to design around existing patents or can freely use a particular approach.

Bottom line

• Gabapentin itself is free to use; no longer subject to the original Pfizer patents.
• Generics are widely available and affordable.
• New patents still exist on specific delivery methods or combination products; careful analysis is needed if you wish to innovate in those areas.

If you’d like help digging into a particular patent or assessing a specific formulation idea, let me know!